Analyst Price Target is $13.17
▲ +206.92% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for 2seventy bio in the last 3 months. The average price target is $13.17, with a high forecast of $26.00 and a low forecast of $5.00. The average price target represents a 206.92% upside from the last price of $4.29.
Current Consensus is
Hold
The current consensus among 8 contributing investment analysts is to hold stock in 2seventy bio. This Hold consensus rating has held steady for over two years.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More